Baxter unveiled its next-generation Vest APX System, featuring patient-centered improvements for those with chronic lung conditions.
RT’s Three Key Takeaways:
- New System Launched: Baxter unveiled The Vest APX System, its next-generation airway clearance device, at the North American Cystic Fibrosis Conference.
- Enhanced Features: The system includes improved comfort, a lighter and more compact design, and intuitive touch-screen controls for easier patient use.
- FDA Clearance: The Vest APX System received FDA 510(k) clearance earlier this year and will be available to order in the fall.
Baxter International Inc unveiled its next-generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference.
The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same airflow technology as the previous version, with enhanced comfort and additional patient-centered features driven by clinician and patient input, according to a release from the company.
“Many patients who are prescribed this therapy use it multiple times a day, every day,” says Jim O’Connell, president of front line care at Baxter, in a release. “With that in mind, it was very important for us to design a solution that fits seamlessly into a patient’s daily routine. The Vest APX System offers next-level comfort, ease of use, and portability, all while maintaining the performance patients and caregivers have depended on for years.”
High-frequency Chest Wall Oscillation Technology
Patients with chronic lung conditions such as cystic fibrosis and bronchiectasis can experience mucus blocking the small airways in their lungs. Mucus can trap bacteria, which can lead to lung inflammation and infections. The Vest APX System uses high-frequency chest wall oscillation (HFCWO) technology to help dislodge mucus from the bronchial walls and mobilize secretions and mucus from the smaller to larger airways where it can be cleared by coughing or suctioning.
Baxter entered the non-invasive respiratory health industry in December 2021 through its acquisition of Hillrom, an airway clearance provider. Its HFCWO technology has been demonstrated to be a safe and effective airway clearance solution for nearly 200,000 patients over the past 35 years and has been tested in more than 60 clinical studies to date, according to data on file at Baxter.
New Features of the Next-Gen Vest
According to Baxter, new features of The Vest APX System include:
- Added comfort: A streamlined, lightweight garment that keeps the abdomen free, a wicking fabric to keep patients cool, and a Velcro brand closure for optimal fit.
- Unique designs: Patients have the option to choose from an expanded selection of new garment colors and designs, including vibrant options for adults and playful options for children.
- Easy to use: User-friendly, intuitive navigation on a touch screen that makes it easy for patients and caregivers to start therapy with one button push. The control unit is 19% smaller and 30% lighter than the previous version and comes with a carrying case.
Patients and care teams also have the option to receive ongoing support with the CARE Connex Program. The program offers touchpoints with Baxter clinical experts throughout the patient care journey to assess and answer questions from patients and caregivers.
Baxter received US Food and Drug Administration 510(k) clearance for The Vest APX System earlier this year. The system will also be showcased at the American College of Chest Physicians (CHEST) annual meeting Oct 6-9 and will be available to order this fall.
Photo caption: The Vest APX
Photo credit: Baxter
